The American Gastroenterological Association (AGA) recommends glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide and liraglutide, as pharmacologic options for the management of obesity [52]. This evidence concerns the gene GLP1R and Obesity.